Keros Therapeutics Email Format

Biotechnology ResearchMassachusetts, United States51-200 Employees

Keros Therapeutics is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapies for disorders linked to dysfunctional signaling within the transforming growth factor-beta (TGF-β) protein family. Its work centers on protein therapeutics that could provide meaningful, potentially disease-modifying benefits for patients affected by these signaling abnormalities. The company’s lead candidate, rinvatercept (KER-065), is being developed for Duchenne muscular dystrophy and amyotrophic lateral sclerosis.

Keros operates in the biotechnology research sector and aims to translate TGF-β signaling insights into therapies for a broad set of related conditions, supported by a mid-sized team. In June 2026, the company announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference, reflecting active engagement with the broader healthcare ecosystem.

Get verified Keros Therapeutics emails free

Company overview Employee directory